Adaptimmune Company

Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom. Stock Symbol: NASDAQ:ADA
Technology: Cell Therapies
Industry: Preventive Medicine
Headquarters: Oxton, York, United Kingdom
Founded Date: 2008
Employees Number: 51-100
Funding Status: IPO

Visit Website
Register and Claim Ownership